Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150091 | 0.87 | CHRM5 (0.42) | MAPTPSMD14KMT2ANPC1MITF | |
| SCHEMBL8038944 | 0.85 | ALDH1A1 (0.50) | MAPTPSMD14KMT2ANPC1MITF | |
| SCHEMBL8021770 | 0.83 | SLC6A2 (0.46) | PSMD14NR1H2NR1H3CHRM5CHKA | |
| Hydrochloric Acid SCHEMBL8040784 | 0.83 | KMT2A (0.49) | MAPTPSMD14KMT2ANPC1MITF | |
| SCHEMBL8039657 | 0.83 | ALDH1A1 (0.54) | MAPTPSMD14KMT2ANPC1MITF | |
| SCHEMBL49134 | 0.83 | CHRM5 (0.52) | MAPTPSMD14NPC1RAB9ANR1H2 | |
| Hydrochloric Acid SCHEMBL8042521 | 0.81 | ALDH1A1 (0.52) | MAPTPSMD14KMT2ANPC1MITF | |
| Hydrochloric Acid SCHEMBL7861604 | 0.81 | ALDH1A1 (0.50) | MAPTPSMD14NPC1RAB9ANR1H2 | |
| Hydrochloric Acid SCHEMBL10705984 | 0.80 | TSHR (0.52) | MAPTPSMD14KMT2ANPC1MITF | |
| SCHEMBL133939 | 0.79 | TSHR (0.55) | MAPTPSMD14KMT2ANPC1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021260438-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | INTOCELL, INC. (KR) | 2021-12-30 | — | — | WO | disclosed |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-1482931-B1 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA INC (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| CN-101613321-A | The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction | TRANSTECH PHARMA INC | 2009-12-30 | — | — | CN | disclosed |
| CN-101597262-A | The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction | TRANSTECH PHARMA INC (US) | 2009-12-09 | — | — | CN | disclosed |
| CN-100525763-C | Mono-and bicyclic pyrrole derivatives inhibiting ligand interaction with higher glycation end product receptors | TRANSTECH PHARMA INC (US) | 2009-08-12 | — | — | CN | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| CN-1633290-A | Mono-and bicyclic pyrrole derivatives inhibiting ligand interaction with higher glycation end product receptors | TRANSTECH PHARMA INC (US) | 2005-06-29 | — | — | CN | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-4935292-A | BONDED CHROMOPHORES FOR FREQUENCY DOUBLING | NORTHWESTERN UNIVERSITY (US) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 526/4885PSMD14 4425/4885KMT2A 4844/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 406/4885PSMD14 4493/4885KMT2A 4802/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 430/4885PSMD14 4469/4885KMT2A 4827/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | MAPT 430/4885PSMD14 4469/4885KMT2A 4827/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 430/4885PSMD14 4469/4885KMT2A 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.